- Previous Close
6.55 - Open
6.45 - Bid 4.90 x 100
- Ask 5.50 x 3000
- Day's Range
6.19 - 6.50 - 52 Week Range
0.00 - 7.38 - Volume
6,511 - Avg. Volume
8,098 - Market Cap (intraday)
113.583M - Beta (5Y Monthly) 1.47
- PE Ratio (TTM)
-- - EPS (TTM)
-1.28 - Earnings Date May 28, 2025 - Jun 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.67
BioHarvest Sciences Inc. operates as a biotechnology company. The company operates through Nutraceuticals and Pharmaceuticals segments. It develops botanical synthesis platform technology to grow the ingredients in any plant enzymes or cells. The company is leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions in nutraceuticals and pharmaceuticals verticals. It also operates as a contract development and manufacturing operation services. In addition, the company offers wellness products. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red grapes. The company operates in Israel and the United States. BioHarvest Sciences Inc. is based in Vancouver, Canada.
www.bioharvest.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BHST
View More
Performance Overview: BHST
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BHST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BHST
View MoreValuation Measures
Market Cap
107.26M
Enterprise Value
115.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.24
Price/Book (mrq)
25.91
Enterprise Value/Revenue
5.14
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-76.65%
Return on Assets (ttm)
-26.95%
Return on Equity (ttm)
--
Revenue (ttm)
22.43M
Net Income Avi to Common (ttm)
-17.19M
Diluted EPS (ttm)
-1.28
Balance Sheet and Cash Flow
Total Cash (mrq)
2.77M
Total Debt/Equity (mrq)
258.44%
Levered Free Cash Flow (ttm)
-7.13M